 visitant ::
identificació
|
|||||||||||||||
|
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español | |||||||||
| Pàgina inicial > Articles > Articles publicats > Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis |
(Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) (Institut d'Investigació Biomèdica Sant Pau) (Hospital Universitari Vall d'Hebron. Institut de Recerca) (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) (Universitat Autònoma de Barcelona) (Institut d'Investigació Biomèdica Sant Pau) (Hospital Universitari Vall d'Hebron) (University of Alberta) (Institut d'Investigació Biomèdica Sant Pau) (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) (Department of Biomedical Research and University Clinic for Visceral Medicine and Surgery. Inselspital) (Institut d'Investigacions Biomèdiques August Pi i Sunyer) (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)| Data: | 2021 |
| Resum: | Background & Aims: Treatment with non-selective beta-blockers (NSBBs) reduces the risk of ascites, which is the most common decompensating event in cirrhosis. This study aimed to assess the ability of a serum microRNA (miRNA) signature to predict ascites formation and the hemodynamic response to NSBBs in compensated cirrhosis. Methods: Serum levels of miR-452-5p, miR-429, miR-885-5p, miR-181b-5p, and miR-122-5p were analyzed in patients with compensated cirrhosis (N = 105). Hepatic venous pressure gradient (HVPG) was measured at baseline, after intravenous propranolol, and 1 year after randomization to NSBBs (n = 52) or placebo (n = 53) (PREDESCI trial). miRNAs were analyzed at baseline and at 1 year. Results: Nineteen patients (18%) developed ascites, of whom 17 developed ascites after 1 year. miR-181b-5p levels at 1 year, but not at baseline, were higher in patients that developed ascites. The AUC of miR-181b-5p at 1 year to predict ascites was 0. 7 (95% CI 0. 59-0. 78). miR-429 levels were lower at baseline in acute HVPG responders to NSBBs (AUC 0. 65; 95% CI, 0. 53-0. 76), but levels at baseline and at 1 year were not associated with the HVPG response to NSBBs at 1 year. Conclusions: Serum miR-181b-5p is a promising non-invasive biomarker to identify patients with compensated cirrhosis at risk of ascites development. Lay summary: Ascites marks the transition from the compensated to decompensated stage in cirrhosis and indicates a worsening in prognosis. There are currently no easily accessible tools to identify patients with compensated cirrhosis at risk of developing ascites. We evaluated the levels of novel molecules termed microRNAs in the blood of patients with compensated cirrhosis and observed that miR-181b-5p can predict which patients are going to develop ascites. |
| Ajuts: | Instituto de Salud Carlos III SAF 2017-86343-R Instituto de Salud Carlos III PI20/01302 Instituto de Salud Carlos III PI18/01901 Instituto de Salud Carlos III CIBEREHD-16PI03 Instituto de Salud Carlos III PI20/00220 Instituto de Salud Carlos III CM18/00091 |
| Nota: | Altres ajuts: Ministerio de Ciencia e Innovación; Fondo Europeo de Desarrollo Regional (FEDER); Gilead Sciences (GLD19/00045). |
| Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.  |
| Llengua: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Matèria: | Ascites ; Beta-blockers ; Cirrhosis ; MicroRNA ; Portal hypertension |
| Publicat a: | JHEP Reports, Vol. 3 Núm. 6 (december 2021) , p. 100368, ISSN 2589-5559 |
